You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

TARGINIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Targiniq patents expire, and when can generic versions of Targiniq launch?

Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries.

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Targiniq

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2025. This may change due to patent challenges or generic licensing.

There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for TARGINIQ
Drug patent expirations by year for TARGINIQ
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TARGINIQ
Generic Entry Date for TARGINIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TARGINIQ

TARGINIQ is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TARGINIQ is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TARGINIQ

Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Oxycodone compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TARGINIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TARGINIQ

When does loss-of-exclusivity occur for TARGINIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 32
Estimated Expiration: ⤷  Try a Trial

Argentina

Patent: 9012
Estimated Expiration: ⤷  Try a Trial

Patent: 8531
Estimated Expiration: ⤷  Try a Trial

Patent: 4161
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 05230826
Estimated Expiration: ⤷  Try a Trial

Patent: 09200335
Estimated Expiration: ⤷  Try a Trial

Patent: 11213801
Estimated Expiration: ⤷  Try a Trial

Patent: 13202453
Estimated Expiration: ⤷  Try a Trial

Patent: 15261590
Estimated Expiration: ⤷  Try a Trial

Patent: 17204741
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 01150
Estimated Expiration: ⤷  Try a Trial

Patent: 52
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0508758
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 57845
Estimated Expiration: ⤷  Try a Trial

Patent: 74121
Estimated Expiration: ⤷  Try a Trial

Patent: 13355
Estimated Expiration: ⤷  Try a Trial

China

Patent: 60994
Estimated Expiration: ⤷  Try a Trial

Patent: 1812065
Estimated Expiration: ⤷  Try a Trial

Patent: 2127086
Estimated Expiration: ⤷  Try a Trial

Patent: 2838607
Estimated Expiration: ⤷  Try a Trial

Patent: 2887903
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 93
Estimated Expiration: ⤷  Try a Trial

Patent: 110376
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0110425
Estimated Expiration: ⤷  Try a Trial

Patent: 0150358
Estimated Expiration: ⤷  Try a Trial

Patent: 0160223
Estimated Expiration: ⤷  Try a Trial

Patent: 0160885
Estimated Expiration: ⤷  Try a Trial

Patent: 0180407
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 11487
Estimated Expiration: ⤷  Try a Trial

Patent: 16327
Estimated Expiration: ⤷  Try a Trial

Patent: 17228
Estimated Expiration: ⤷  Try a Trial

Patent: 17841
Estimated Expiration: ⤷  Try a Trial

Patent: 20171
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 30151
Estimated Expiration: ⤷  Try a Trial

Patent: 05683
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Patent: 19846
Estimated Expiration: ⤷  Try a Trial

Patent: 26132
Estimated Expiration: ⤷  Try a Trial

Patent: 0700214
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 066953
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 3208
Estimated Expiration: ⤷  Try a Trial

Patent: 0601520
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 30151
Estimated Expiration: ⤷  Try a Trial

Patent: 05683
Estimated Expiration: ⤷  Try a Trial

Patent: 11839
Estimated Expiration: ⤷  Try a Trial

Patent: 14589
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Patent: 19846
Estimated Expiration: ⤷  Try a Trial

Patent: 26132
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 0070284
Estimated Expiration: ⤷  Try a Trial

Patent: 43
Estimated Expiration: ⤷  Try a Trial

Georgia, Republic of

Patent: 0094655
Estimated Expiration: ⤷  Try a Trial

Germany

Patent: 2005021371
Estimated Expiration: ⤷  Try a Trial

Patent: 2005026786
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 98745
Estimated Expiration: ⤷  Try a Trial

Patent: 55728
Estimated Expiration: ⤷  Try a Trial

Patent: 55729
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 28233
Estimated Expiration: ⤷  Try a Trial

Patent: 29913
Estimated Expiration: ⤷  Try a Trial

Patent: 36451
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 8038
Estimated Expiration: ⤷  Try a Trial

Patent: 3889
Estimated Expiration: ⤷  Try a Trial

Patent: 3890
Estimated Expiration: ⤷  Try a Trial

Patent: 4050
Estimated Expiration: ⤷  Try a Trial

Patent: 5298
Estimated Expiration: ⤷  Try a Trial

Patent: 1117
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 12294
Estimated Expiration: ⤷  Try a Trial

Patent: 18223
Estimated Expiration: ⤷  Try a Trial

Patent: 78486
Estimated Expiration: ⤷  Try a Trial

Patent: 43991
Estimated Expiration: ⤷  Try a Trial

Patent: 03392
Estimated Expiration: ⤷  Try a Trial

Patent: 07531756
Estimated Expiration: ⤷  Try a Trial

Patent: 11157370
Estimated Expiration: ⤷  Try a Trial

Patent: 12072162
Estimated Expiration: ⤷  Try a Trial

Patent: 12188439
Estimated Expiration: ⤷  Try a Trial

Patent: 14139205
Estimated Expiration: ⤷  Try a Trial

Patent: 15187134
Estimated Expiration: ⤷  Try a Trial

Patent: 17125052
Estimated Expiration: ⤷  Try a Trial

Patent: 18184462
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 14589
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 3205
Estimated Expiration: ⤷  Try a Trial

Patent: 4985
Estimated Expiration: ⤷  Try a Trial

Patent: 2063
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 3228
Estimated Expiration: ⤷  Try a Trial

Patent: 20008878
Estimated Expiration: ⤷  Try a Trial

Montenegro

Patent: 299
Estimated Expiration: ⤷  Try a Trial

Patent: 411
Estimated Expiration: ⤷  Try a Trial

Patent: 482
Estimated Expiration: ⤷  Try a Trial

Patent: 068
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 492
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 9430
Estimated Expiration: ⤷  Try a Trial

Patent: 1326
Estimated Expiration: ⤷  Try a Trial

Patent: 2862
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 7669
Estimated Expiration: ⤷  Try a Trial

Patent: 064935
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 050880
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 30151
Estimated Expiration: ⤷  Try a Trial

Patent: 05683
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Patent: 19846
Estimated Expiration: ⤷  Try a Trial

Patent: 26132
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 30151
Estimated Expiration: ⤷  Try a Trial

Patent: 05683
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Patent: 19846
Estimated Expiration: ⤷  Try a Trial

Patent: 26132
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 693
Estimated Expiration: ⤷  Try a Trial

Patent: 891
Estimated Expiration: ⤷  Try a Trial

Patent: 598
Estimated Expiration: ⤷  Try a Trial

Patent: 941
Estimated Expiration: ⤷  Try a Trial

Patent: 000
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 0735
Estimated Expiration: ⤷  Try a Trial

Patent: 0736
Estimated Expiration: ⤷  Try a Trial

Patent: 201406658V
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 30151
Estimated Expiration: ⤷  Try a Trial

Patent: 05683
Estimated Expiration: ⤷  Try a Trial

Patent: 16837
Estimated Expiration: ⤷  Try a Trial

Patent: 19846
Estimated Expiration: ⤷  Try a Trial

Patent: 26132
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0607181
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 0930730
Estimated Expiration: ⤷  Try a Trial

Patent: 0993911
Estimated Expiration: ⤷  Try a Trial

Patent: 1200700
Estimated Expiration: ⤷  Try a Trial

Patent: 1410141
Estimated Expiration: ⤷  Try a Trial

Patent: 070022033
Estimated Expiration: ⤷  Try a Trial

Patent: 090104145
Estimated Expiration: ⤷  Try a Trial

Patent: 100069719
Estimated Expiration: ⤷  Try a Trial

Patent: 110110377
Estimated Expiration: ⤷  Try a Trial

Patent: 120046309
Estimated Expiration: ⤷  Try a Trial

Patent: 120106784
Estimated Expiration: ⤷  Try a Trial

Patent: 130020962
Estimated Expiration: ⤷  Try a Trial

Patent: 140021716
Estimated Expiration: ⤷  Try a Trial

Patent: 140133615
Estimated Expiration: ⤷  Try a Trial

Patent: 150046393
Patent: 25 PPM 미만의 14-하이드록시코데이논을 가지는 염산 옥시코돈의 제조방법 (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)
Estimated Expiration: ⤷  Try a Trial

Patent: 180088505
Patent: 25 PPM 미만의 14-하이드록시코데이논을 가지는 염산 옥시코돈의 제조방법 (25 14- PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)
Estimated Expiration: ⤷  Try a Trial

Patent: 200000499
Patent: 25 PPM 미만의 14-하이드록시코데이논을 가지는 염산 옥시코돈의 제조방법 (25 14- PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 62282
Estimated Expiration: ⤷  Try a Trial

Patent: 35618
Estimated Expiration: ⤷  Try a Trial

Patent: 66363
Estimated Expiration: ⤷  Try a Trial

Patent: 85576
Estimated Expiration: ⤷  Try a Trial

Patent: 65287
Estimated Expiration: ⤷  Try a Trial

Patent: 38727
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 65880
Estimated Expiration: ⤷  Try a Trial

Patent: 83944
Estimated Expiration: ⤷  Try a Trial

Patent: 0540177
Estimated Expiration: ⤷  Try a Trial

Patent: 1231469
Estimated Expiration: ⤷  Try a Trial

Patent: 1509943
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 06312
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 411
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TARGINIQ around the world.

Country Patent Number Title Estimated Expiration
Taiwan 200403996 Pharmaceutical preparation containing oxycodone and naloxone ⤷  Try a Trial
European Patent Office 2314589 Procédé de préparation d'hydrochlorure d'oxycodone contenant moins de 25 ppm de 14-hydroxycodéinone (Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone) ⤷  Try a Trial
New Zealand 524282 Opioid agonist/antagonist combinations in controlled release dosage form ⤷  Try a Trial
Finland U20070322 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TARGINIQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 122013000082 Germany ⤷  Try a Trial PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530
1685839 CA 2013 00052 Denmark ⤷  Try a Trial PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530
1685839 C300619 Netherlands ⤷  Try a Trial PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530
1685839 92292 Luxembourg ⤷  Try a Trial PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.